Scoring Method to Identify Low HCC Risk in Patients With Advanced Fibrosis After SVR to HCV Therapy

November 8-12, 2019; Boston, Massachusetts
External validation supports scoring system for identifying patients with low risk of HCC following SVR.
Format: Microsoft PowerPoint (.ppt)
File Size: 172 KB
Released: November 18, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.

Related Content

Download key slides describing lessons learned in delivery of care from the COVID-19 pandemic worth carrying forward in the management of viral hepatitis.

Gregory Dore, MBBS, PhD, FRACP, MPH Stacey Trooskin, MD, PhD, MPH Released: September 23, 2021

Download free slides reviewing key data and AASLD guidance on managing HBV infection during pregnancy

Joseph Ahn, MD, MS, MBA Released: July 8, 2021

Brief Clinical Care Options (CCO) presentation on AASLD guidance on treatment indications and treatment options for pregnant women with chronic HBV infection

Joseph Ahn, MD, MS, MBA Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: July 8, 2021 Expired: July 7, 2022

From Clinical Care Options (CCO), download a PDF featuring expert answers to HCP questions on immunotherapy for patients with advanced HCC

Released: June 29, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue